摘要
Human hepatitis E virus (HHEV) is the proposed name for a diverse group of RNA viruses from the family Hepeviridae that cause acute hepatitis among humans.Waterborne strains are regularly imported into Europe by international travelers,and virus transmission of zoonotic strains via contaminated aliments is involved in autochthonous cases.Therefore,in Europe,hepatitis E displays a unique dual character,having features of both imported and autochthonous infections.Environmental involvement of waterborne and zoonotic diseases puts alimentary safety at risk.In addition,it may lead to serious health problems derived from persistent infection among patients with immune impairment due to organ transplant,cancer,or human immunodeficiency virus infection.Although the European health authorities know at present that HHEV represents a problem worthy of consideration,the actual incidence of the disease in Europe is unknown,and attempts to ascertain the prevalence of the infection is hampered by unresolved technical issues.In order to determine the burden of hepatitis E in Europe,the World Health Organization Regional Office and the European Centre for Disease Prevention and Control should pay specific attention to hepatitis E,and research efforts in the continent should be transnational and collaborative.Development of a specific European network for hepatitis E would help to achieve these goals.
Human hepatitis E virus (HHEV) is the proposed name for a diverse group of RNA viruses from the family Hepeviridae that cause acute hepatitis among humans.Waterborne strains are regularly imported into Europe by international travelers,and virus transmission of zoonotic strains via contaminated aliments is involved in autochthonous cases.Therefore,in Europe,hepatitis E displays a unique dual character,having features of both imported and autochthonous infections.Environmental involvement of waterborne and zoonotic diseases puts alimentary safety at risk.In addition,it may lead to serious health problems derived from persistent infection among patients with immune impairment due to organ transplant,cancer,or human immunodeficiency virus infection.Although the European health authorities know at present that HHEV represents a problem worthy of consideration,the actual incidence of the disease in Europe is unknown,and attempts to ascertain the prevalence of the infection is hampered by unresolved technical issues.In order to determine the burden of hepatitis E in Europe,the World Health Organization Regional Office and the European Centre for Disease Prevention and Control should pay specific attention to hepatitis E,and research efforts in the continent should be transnational and collaborative.Development of a specific European network for hepatitis E would help to achieve these goals.
